Neoadjuvant Concurrent Chemoradiotherapy for Duodenal-invasive Ascending Colon Cancer: Case Series
10.52927/jdcr.2026.14.1.109
- Author:
Seong Hyun KOH
1
;
Jae Hyun KIM
;
Seun Ja PARK
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
- Publication Type:CASE REPORT
- From:
Journal of Digestive Cancer Research
2026;14(1):109-114
- CountryRepublic of Korea
- Language:English
-
Abstract:
Duodenal invasion by ascending colon cancer is an uncommon and challenging manifestation of locally advanced right-sided colon cancer. Its optimal management remains debatable, particularly regarding the use of neoadjuvant concurrent chemoradiotherapy (CCRT). We retrospectively reviewed seven patients (aged 63–80 years) with ascending colon adenocarcinoma with duodenal invasion who were treated with neoadjuvant CCRT between 2012 and 2025 at a single tertiary center. Clinical staging ranged from stage IIC to IVB. Treatment strategies included neoadjuvant CCRT followed by curative-intent surgery when feasible and palliative chemotherapy and/or radiotherapy in advanced or inoperable cases. Among the seven patients, five underwent curative surgery following CCRT. Of these, four achieved long-term, recurrencefree survival for 99 months or more (average 102.5 months). One experienced recurrence after initial treatment and died of progressive disease. The remaining two patients did not undergo surgery because of disease progression or poor response to initial therapy, resulting in death or loss to follow-up. Histology revealed moderately to poorly differentiated adenocarcinoma and signet ring cell carcinoma. Neoadjuvant CCRT is feasible and effective in some patients with ascending colon cancer and duodenal invasion, supporting en bloc resection while minimizing surgical morbidity. Prospective studies are warranted to establish optimal treatment protocols.
